文献速递肝病

代谢功能障碍一般人群中无创检查对临床显著肝病的诊断准确性和效用比较

Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction.
PubMed 文献 · Hepatology · 2025-05-07

在代谢功能障碍的meta队列(鹿特丹研究和美国国家健康与营养调查)11,404名18-80岁参与者中比较10种无创检查对临床相关肝病的诊断准确性。MAF-5对肝硬度增高(≥8 kPa AUC 0.80;≥12 kPa AUC 0.87)和进展期纤维化(AUC 0.90)判别最佳,纤维化NASH指数和MAF-5对代谢功能障碍相关脂肪性肝炎检测最佳(AUC 0.93和0.92,p=ns),SAFE对肝硬化最佳(AUC 0.92)。MAF-5在保持80%敏感性时转诊率低于FIB-4且特异性更高,年龄依赖评分在年轻人群中敏感性较低。

要点

  • MAF-5对肝硬度≥8 kPa的AUC为0.80,对≥12 kPa为0.87,对进展期纤维化为0.90。
  • 纤维化NASH指数和MAF-5对MASH的AUC分别为0.93和0.92(p=ns),SAFE对肝硬化的AUC为0.92。
  • 达到肝硬度≥8 kPa 80%敏感性时,MAF-5转诊率42%低于FIB-4的77%,特异性62%高于24%。

核心结论

  • 在10种无创检查中,MAF-5对除肝硬化外的所有病症判别最佳,SAFE对肝硬化准确性最高。
  • FIB-4表现较差,采用更准确的无创检查如MAF-5可改善低患病率人群的转诊路径。

研究设计与样本

  • 在代谢功能障碍的meta队列(鹿特丹研究和美国国家健康与营养调查)中,纳入18-80岁参与者,分析11,404人。
  • 评估10种无创检查对临床相关病症(肝硬度增高、高危MASH、进展期纤维化或肝硬化)的诊断准确性。
  • 亚组分析按年龄组和糖尿病/肥胖状态分层。

主要发现

  • MAF-5对肝硬度≥8 kPa的AUC为0.80,对≥12 kPa的AUC为0.87,对进展期纤维化的AUC为0.90。
  • 纤维化NASH指数和MAF-5对MASH的AUC分别为0.93和0.92(p=ns),SAFE对肝硬化的AUC为0.92。
  • 为达到肝硬度≥8 kPa 80%敏感性,MAF-5对应截断值的转诊率为42%,低于FIB-4的77%;特异性为62%,高于FIB-4的24%。
  • MAF-5对肝硬度≥12 kPa和进展期纤维化的检测也优于其他检查。
  • 年龄依赖评分在年轻人群中敏感性较低:在18-35岁人群中,转诊无创检查评分最高的20%人群时,FIB-4、SAFE、NAFLD纤维化评分、FORNS和Hepamet纤维化评分对肝硬度≥8 kPa的敏感性均<10%,而纤维化NASH指数和MAF-5分别为40%和71%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Screening for liver disease in the general population requires accurate non-invasive tests (NITs). A head-to-head comparison of NITs for early detection of clinically relevant liver disease among the target population for screening is lacking. APROACH AND RESULTS: Among the meta-cohort (Rotterdam Study and National Health and Nutrition Examination Survey) with metabolic dysfunction aged 18-80 years, 10 NITs were investigated. The diagnostic accuracy for clinically relevant conditions [increased liver stiffness measurement (LSM), at-risk metabolic dysfunction-associated steatohepatitis, advanced fibrosis, or cirrhosis) was assessed. Subgroup analysis included stratification by age group and diabetes/obesity status.We analysed 11,404 participants. Metabolic dysfunction-associated fibrosis 5 (MAF-5) obtained the highest AUC for increased LSM (≥8 kPa: 0.80; ≥12 kPa: 0.87) and advanced fibrosis (AUC: 0.90). Fibrotic NASH index and MAF-5 performed best for detecting metabolic dysfunction-associated steatohepatitis (AUC: 0.93 and AUC: 0.92, p =ns) and SAFE for cirrhosis (AUC: 0.92). To obtain 80% sensitivity for LSM ≥8 kPa, the corresponding MAF-5 cut-off resulted in fewer referrals (42%) compared to fibrosis-4 index (77%) and higher specificity (62% vs. 24%); MAF-5 was also superior for detection of LSM ≥12 kPa and advanced fibrosis. Age-dependent scores yielded lower sensitivity among younger individuals, for example, by referring 20% of the population with the highest NIT scores, the fibrosis-4 index, steatosis-associated fibrosis estimator, NAFLD fibrosis score, FORNS, and Hepamet fibrosis score yielded <10% sensitivity for LSM ≥8 kPa among individuals aged 18-35 years, while fibrotic NASH index and MAF-5 obtained 40% and 71%. CONCLUSIONS: Of the 10 investigated NITs, MAF-5 discriminated best between all conditions except cirrhosis, for which the steatosis-associated fibrosis estimator yielded the highest accuracy. The performance of the fibrosis-4 index was poor, implying that referral pathways for significant liver disease in low-prevalence populations can be improved when more accurate NITs such as MAF-5 are employed.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. van Kleef LA, Pustjens J, Schattenberg JM, et al. Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction. Hepatology. 2025. PMID: 40331893. doi:10.1097/HEP.0000000000001356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。